X4 Pharmaceuticals Inc (NASDAQ:XFOR) — Market Cap & Net Worth
Market Cap & Net Worth: X4 Pharmaceuticals Inc (XFOR)
X4 Pharmaceuticals Inc (NASDAQ:XFOR) has a market capitalization of $381.99 Million ($381.99 Million) as of June 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #13802 globally and #3270 in its home market, demonstrating a 5.19% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying X4 Pharmaceuticals Inc's stock price $4.05 by its total outstanding shares 94319696 (94.32 Million). Review debt load of X4 Pharmaceuticals Inc to assess the company's total debt and financial obligations.
X4 Pharmaceuticals Inc Market Cap History: 2017 to 2026
X4 Pharmaceuticals Inc's market capitalization history from 2017 to 2026. Data shows change from $7.22 Billion to $381.99 Million (-29.76% CAGR).
Index Memberships
X4 Pharmaceuticals Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.42 Trillion | 0.02% | #368 of 976 |
|
NASDAQ Composite
IXIC
|
$40.74 Trillion | 0.00% | #1341 of 3165 |
Weight: X4 Pharmaceuticals Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
X4 Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how X4 Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
10.74x
X4 Pharmaceuticals Inc's market cap is 10.74 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $1.31 Billion | $3.50 Million | -$33.28 Million | 375.12x | N/A |
| 2019 | $1.01 Billion | $3.00 Million | -$52.81 Million | 336.41x | N/A |
| 2020 | $606.48 Million | $3.00 Million | -$62.13 Million | 202.16x | N/A |
| 2024 | $69.19 Million | $2.56 Million | -$37.45 Million | 27.06x | N/A |
| 2025 | $377.28 Million | $35.11 Million | -$79.20 Million | 10.74x | N/A |
Competitor Companies of XFOR by Market Capitalization
Companies near X4 Pharmaceuticals Inc in the global market cap rankings as of June 19, 2026.
Key companies related to X4 Pharmaceuticals Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #444 globally with a market cap of $62.63 Billion USD.
- UCB SA (BR:UCB): Ranked #549 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $458.99 |
| #444 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.63 Billion | $607.93 |
| #549 | UCB SA | BR:UCB | $49.68 Billion | €252.40 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €780.20 |
X4 Pharmaceuticals Inc Historical Marketcap From 2017 to 2026
Between 2017 and today, X4 Pharmaceuticals Inc's market cap moved from $7.22 Billion to $ 381.99 Million, with a yearly change of -29.76%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $381.99 Million | +1.25% |
| 2025 | $377.28 Million | +445.26% |
| 2024 | $69.19 Million | -12.56% |
| 2023 | $79.13 Million | -15.51% |
| 2022 | $93.66 Million | -56.64% |
| 2021 | $215.99 Million | -64.39% |
| 2020 | $606.48 Million | -39.91% |
| 2019 | $1.01 Billion | -23.13% |
| 2018 | $1.31 Billion | -81.82% |
| 2017 | $7.22 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 18th, 2026 the market cap of X4 Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $381.99 Million USD |
| MoneyControl | $381.99 Million USD |
| MarketWatch | $381.99 Million USD |
| marketcap.company | $381.99 Million USD |
| Reuters | $381.99 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About X4 Pharmaceuticals Inc
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections… Read more